Skip to content
Citation only via OpenAlex

Interactions Between Statins, Exercise, and Health: A Clinical Update

Harrison D. Stierwalt, Audrey E. McCalley, Colin S. McCoin, John P. Thyfault

Journal of Clinical Exercise Physiology · 2022 · ▲ 3 citations

Abstract

Cardiovascular disease (CVD) is a major source of morbidity and mortality across the globe (1). The Global Burden of Disease study, which includes epidemiological estimates of disease from 204 countries between 1990 and 2019, established that CVD is the leading cause of death worldwide (2). CVD is also a major source of reduced quality of life due to related illnesses. In 2019, there were 523 million cases of CVD, 18.6 million deaths, 34.4 million living with a CVD-related disability, and nearly 400 million years of life lost or disability-adjusted life years due to CVD (2). Considering the large impact CVD has on disability-adjusted life years, improving healthspan(definition), defined as the period someone spends healthy and free from chronic disease (3,4), is becoming critically important as modern medical capability improves lifespan expectancy. J Clin Exerc Physiol. 2022;11(2):54–61.Regular exercise is a commonly prescribed therapeutic intervention for the mitigation of CVD and improvements to healthspan (5–8), which is particularly important in older individuals (9). However, we and others have also advocated that daily exercise (or moderate to vigorous physical activity) is obligatory for normal health and wellness and not just an intervention that improves health (10). A common measurement used to assess overall health and fitness is cardiorespiratory fitness (CRF), which can be increased or maintained during the aging process with regular moderate to vigorous exercise (11,12). Recent reviewers have summarized evidence indicating that improvements in CRF play an integral role in reducing not only CVD but also incident myocardial infarction, hypertension, diabetes, atrial fibrillation, heart failure, stroke, and all-cause mortality (13,14). Moreover, the American Heart Association published a position paper stating that CRF should be a vital sign for clinical care (15). Hence, exercise has been explored and used as an intervention that can both prevent and, in some cases, treat various chronic metabolic diseases. Despite strong evidence that physical activity reduces the risk of preventable chronic disease conditions, including CVD, authors of a 2008 study reported the number of people who met recommended governmental activity guidelines in the US as extraordinarily low, including >90% of US adults not meeting goals of 150 min·week−1 of moderate to vigorous activity (16). Authors of a more recent study from 2018, however, reported the number of US adults between the ages of 18 and 64 who did not meet the recommended physical activity guidelines decreased (77.1%) between 2010 and 2015, yet those meeting the recommended guidelines remain low (17). Additionally, the World Health Organization reported in 2018 that 80% of adolescents do not meet recommended physical activity criteria across the globe (18). Since exercise goals are not being met, clinicians have increasingly turned to pharmacotherapy to prevent and/or treat chronic diseases. As exercise is a common intervention prescribed to improve healthspan, there is a critical need to understand the interactions of exercise when used in combination with medications prescribed for chronic disease prevention such as CVD.Statins are a common prescription as a secondary prevention method to reduce the risk for CVD events/revascularization interventions (19–21). Statins are cholesterol-lowering drugs that do so via inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), a rate-limiting enzyme for hepatic cholesterol synthesis (22,23). There are 2 forms of statins, lipophilic and hydrophilic, due to polar or nonpolar substituents. The lipophilic statins (simvastatin, atorvastatin, etc.) move passively through the cell membrane resulting in extrahepatic tissue uptake in addition to the liver, whereas hydrophilic statins (pravastatin) require carrier-mediated uptake and primarily target the liver (22). Statin therapy is a highly effective secondary prevention method that reduces CVD-related mortality, all-cause mortality, coronary events, ischemic strokes, and postmyocardial infarction recovery (20,21,24,25). While statins generally achieve similar effects, some contend that high-intensity statins (i.e., rosuvastatin (20 or 40 mg) and/or atorvastatin (40 or 80 mg)) are preferred in secondary prevention and yield significantly lower subsequent mortality rates than other statins (26). In the past, statins were primarily prescribed after a CVD event, for those with type 2 diabetes, or for those with familial hypercholesteremia (FH). However, guidelines were established by the American Heart Association/American College of Cardiology in 2013 that sought to dramatically increase statin use for primary prevention (27). A recent 20-year follow up of children taking statins for FH revealed a reduced risk for CVD in adulthood (28). Because of these guidelines and strong evidence for reducing CVD events, statins have become some of the most widely prescribed drugs in the world. Over 43 million Americans are taking a statin, and atorvastatin was the second most prescribed medication in the world (104,000,000) in 2019 (3,29). As statin therapy use becomes more common, its benefits and risks must be better understood so informed decisions can be made. This is particularly important when considering statins as primary prevention care in disease-free individuals at increasingly younger ages (30), including usage in children with extreme obesity or FH (31).While statins and regular exercise are independently effective treatments for reducing CVD risk, authors of one large study in a cohort of VA patients suggest that combined treatment significantly reduces CVD risk to an even greater degree than either exercise or statin therapy alone (32). However, statin therapy is not without risk for potential adverse side effects, including statin-associated muscle symptoms (SAMSs), gastro-intestinal discomfort, fatigue, liver enzyme elevation, mitochondrial

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.31189/2165-6193-11.2.54
Canonical
link ↗
Fetched
2026-10-11 MST

Cite this

APA
Stierwalt, H.D., McCalley, A.E., McCoin, C.S., &amp; Thyfault, J.P. (2022). Interactions Between Statins, Exercise, and Health: A Clinical Update. <em>Journal of Clinical Exercise Physiology</em>. https://doi.org/10.31189/2165-6193-11.2.54
Vancouver
Stierwalt HD, McCalley AE, McCoin CS, Thyfault JP. Interactions Between Statins, Exercise, and Health: A Clinical Update. Journal of Clinical Exercise Physiology. 2022. doi:10.31189/2165-6193-11.2.54.
BibTeX
@article{harrison2022Intera, title = {Interactions Between Statins, Exercise, and Health: A Clinical Update}, author = {Harrison D. Stierwalt and Audrey E. McCalley and Colin S. McCoin and John P. Thyfault}, journal = {Journal of Clinical Exercise Physiology}, year = {2022}, doi = {10.31189/2165-6193-11.2.54}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings